BOTHELL, WA and VANCOUVER, BC, Nov. 9, 2012 /PRNewswire/ - OncoGenex
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott
Cormack, President and Chief Executive Officer, will provide a
corporate presentation at the Lazard Capital Markets Healthcare
Conference on Wednesday, November 14, 2012 at 10:00 a.m. ET at the
Pierre Hotel in New York City.
Live audio webcasts can be accessed through the Investor Relations page
of the OncoGenex website at www.oncogenex.com. Webcast replays will be archived for 60 days.
OncoGenex is a biopharmaceutical company committed to the development
and commercialization of new therapies that address treatment
resistance in cancer patients. OncoGenex has a diverse oncology
pipeline, with each product candidate having a distinct mechanism of
action and representing a unique opportunity for cancer drug
development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NYSE:
TEVA) have entered a global collaboration and license agreement to
develop and commercialize OncoGenex' lead drug candidate, custirsen.
Custirsen is currently in Phase 3 clinical development as a treatment
in men with metastatic castrate-resistant prostate cancer. OGX-427 is
in Phase 2 clinical development and OGX-225 is currently in
pre-clinical development. More information is available at www.OncoGenex.com
SOURCE OncoGenex Pharmaceuticals, Inc.